Acumyn’s AQUA platform has the power to automate quality control software and hardware, which will improve efficiency and workflows in radiation therapy departments—including providing automated morning QA for radiation therapy clinics and hospitals. PTW has become one of the first dosimeter manufacturers to integrate their technology—PTW’s network-capable UNIDOSwebline universal dosimeter—with the AQUA platform to realize these benefits.
Ferhan Bulca, CEO of Acumyn, says “We believe that customers have been looking for an integrated and automated tool for routine QC, and this collaboration with PTW and their connected dosimeter is a giant step toward making those hopes and aspirations a reality.”
Bernd Allgaier, Head of Product Management at PTW quote “Our UNIDOSwebline has been the dosimeter of choice around the world from a performance standpoint, and we’re proud that including modern network features can enable exciting new applications like this integration with AQUA to automate functions within a busy clinic.-”
Under an exclusive global agreement AQUA is sold and marketed by Elekta who will be demonstrating this vendor-neutral system on their booth at the 3rd ESTRO Forum in Barcelona, Spain in April 2015. Demonstrations will highlight AQUA’s integration with Elekta Linacs, the UNIDOSwebline dosimeter as well as other QA devices and radiation therapy hardware.
Acumyn is the Ontario-based company behind the development of AQUA, an end-to-end system for managing department-level quality assurance workflows and scheduling in radiation therapy that provides a software link between the disparate systems in a department. PTW is a German-based leading provider of dosimetry and quality control equipment used in radiation therapy and other medical fields.
[UHN article: UHN Research ]
University Health Network (UHN) and its spin-off company, Acumyn Inc., have secured an exclusive development and global distribution agreement with one of the world’s biggest radiation therapy companies, Elekta Ltd, to bring to market UHN’s AQUA quality management system software for radiation therapy clinics. The agreement will see UHN’s award-winning AQUA platform developed into a marketable product by Acumyn and then offered to cancer clinics around the world by Elekta, a leading manufacturer of linear accelerators for cancer treatment.
AQUA is a comprehensive software platform that coordinates and centralizes all of the quality assurance tests that need to be performed in a radiotherapy clinic, helping to manage the complexity of these testing requirements.
“AQUA fills a big gap that customers have today. A linear accelerator and associated devices need to be calibrated and maintained on a regular basis. AQUA provides a software link between all the disparate systems and manages the workload, scheduling and reporting of routine QA tasks,” says Dee Mathieson, Senior Vice President, Oncology Business Line Management at Elekta.
In use for the past two years in Toronto at UHN’s Princess Margaret Cancer Centre, a top-five global cancer hospital, AQUA is a vendor-neutral product that has successfully connected, calibrated and managed over 20 of UHN’s cancer therapy machines. It was originally developed and clinically implemented by Drs. David Jaffray and Daniel Létourneau, of UHN’s Princess Margaret Cancer Center and TECHNA Institute.
“The current model for quality control (QC) in radiation oncology is to perform basic QC tests daily to detect machine performance while higher accuracy QC tests are performed less frequently (e.g. monthly) due to their time consuming nature,” says Dr Daniel Létourneau, Associate Head of Physics at the Princess Margaret Cancer Center. “With AQUA, high accuracy QC tests can now be performed daily in order to assess true machine performance and optimize the accuracy of radiation oncology treatment delivery.”
Acumyn Inc. was spun out of UHN with the purpose of bringing AQUA to market.
“We are delighted to have solidified this commercial relationship and cooperation with Elekta which allowed Acumyn to complete its incubation phase. It is an important milestone in terms of commercializing UHN technologies and creating high-quality local jobs and globally-significant healthcare products,” says Mark Taylor, UHN’s Director of Commercialization, Techna.
“Securing global distribution for a product while it is still in development is a huge achievement,” says Dr. Ferhan Bulca, Acumyn’s CEO. “It speaks to the clear need for a product like AQUA to simplify and eliminate human error and ensure that cancer therapy components are aligned to deliver the right amount of radiation to the right areas of the body.”
Elekta will begin piloting Acumyn’s market-ready version of AQUA starting in January 2015, before adding it to its commercial portfolio in April 2015.
For more information:
Mark Taylor, Director of Commercialization, Techna, UHN Technology Development & Commercialization
Dr. Ferhan Bulca, CEO Acumyn Inc.
T: (416) 854-6599; E: email@example.com
TORONTO, December 2 – Acumyn is proud to announce an exclusive agreement with Elekta to commercialize its integrated Quality Management System, AQUA. The system enables multiple mechanical, dosimetric and imaging QA tests to be conducted, analyzed and reported across the radiotherapy clinic.
Ferhan Bulca, Chief Executive Officer at Acumyn says: “Elekta is the ideal partner to Acumyn to deliver AQUA to clinics and hospitals globally. Acumen’s expertise in research and development of quality control and management software is complemented by Elekta’s global customer base in radiation therapy.”
In collaboration with Princess Margaret Cancer Centre in Toronto, Elekta has developed a specialized version of the AQUA system, which is based on a system version that has been in use for over a year, connecting more than 20 machines.
Bulca says: “AQUA is a proven department-level device quality control and management software that has been in daily operations at Princess Margaret Cancer Centre, one of top-five cancer research centres in the world.”
Dee Mathieson, Senior Vice President, Oncology Business Line Management at Elekta adds: “Because AQUA has been developed from a QMS already in clinical practice, it very closely matches the practical, day-to-day requirements of our customers. The system follows Elekta’s open source philosophy and will seamlessly link a range of equipment – regardless of vendor – throughout a typical radiotherapy department.”
AQUA will initially be piloted at selected sites before it is added to Elekta’s commercial portfolio.
Acumyn is a spin-off company from Princess Margaret Cancer Centre and University Health Network, Toronto, Ontario, Canada. A highly focused research and development company, Acumyn is commercializing a department-level machine quality control software platform for radiation therapy devices. With its software platform, Acumyn helps clinics provide radiation therapy treatment with full confidence, enabling clinicians to cure more cancer patients than ever before by exploiting full performance potential of their devices and using high-precision techniques. Website: www.acumyn.com.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elect employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com